disability

Roches fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the…

2 weeks ago

Startek honored with the AAA DI-verse Certification for disability inclusion excellence

Recognition marks Startek's commitment to building an inclusive and accessible workplace for all MUMBAI, India, Oct. 24, 2025 /PRNewswire/ -- Startek®,…

4 months ago